NCT04576728 - Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19 | Biotech Hunter

Enrollment

166

Participants

Timeline

Start Date

October 6, 2020

Primary Completion Date

June 29, 2021

Study Completion Date

June 29, 2021

Conditions

Covid19

Interventions

DRUG

Trimodulin

IMP will be administered via IV infusion on 5 consecutive days.

OTHER

Placebo (human albumin 1%)

IMP will be administered via IV infusion on 5 consecutive days.

Trial Locations (17)

75020

Investigational site # 3304, Paris

75877

Investigational Site # 3301, Paris

111539

Investigational site # 0702, Moscow

119048

Investigational site # 0706, Moscow

125015

Investigational site # 0711, Moscow

125367

Investigational Site # 0704, Moscow

129301

Investigational site # 0708, Moscow

197706

Investigational site # 0701, Saint Petersburg

650066

Investigational site # 0707, Kemerovo

660062

Investigational site # 0709, Krasnoyarsk

90020-090

Investigational site # 5503, Porto Alegre

09030-010

Investigational site # 5502, Santo André

09080-110

Investigational site # 5505, Santo André

05403-000

Investigational site # 5501, São Paulo

42 055

Investigational site # 3305, Saint-Etienne

Unknown

Investigational Site # 3401, Barcelona

Investigational Site # 3402, Madrid